Premium
Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester disease
Author(s) -
Cohen Aubart Fleur,
Emile JeanFrançois,
Maksud Philippe,
Galanaud Damien,
Cluzel Philippe,
Benameur Neila,
Aumaitre Olivier,
Amoura Zahir,
Haroche Julien
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14284
Subject(s) - vemurafenib , mek inhibitor , trametinib , kras , medicine , erdheim–chester disease , cancer research , mapk/erk pathway , kinase , biology , melanoma , histiocytosis , cancer , disease , metastatic melanoma , colorectal cancer , microbiology and biotechnology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom